SHINE Medical Technologies LLC, 47557-47558 [2019-19534]

Download as PDF khammond on DSKBBV9HB2PROD with NOTICES Federal Register / Vol. 84, No. 175 / Tuesday, September 10, 2019 / Notices Based upon this information, the Secretary will establish an electronic docket for the hearing in this proceeding if the Secretary has not already established an electronic docket. Information about applying for a digital ID certificate is available on the NRC’s public website at https:// www.nrc.gov/site-help/e-submittals/ getting-started.html. Once a participant has obtained a digital ID certificate and a docket has been created, the participant can then submit adjudicatory documents. Submissions must be in Portable Document Format (PDF). Additional guidance on PDF submissions is available on the NRC’s public website at https://www.nrc.gov/ site-help/electronic-sub-ref-mat.html. A filing is considered complete at the time the document is submitted through the NRC’s E-Filing system. To be timely, an electronic filing must be submitted to the E-Filing system no later than 11:59 p.m. Eastern Time on the due date. Upon receipt of a transmission, the EFiling system time-stamps the document and sends the submitter an email notice confirming receipt of the document. The E-Filing system also distributes an email notice that provides access to the document to the NRC’s Office of the General Counsel and any others who have advised the Office of the Secretary that they wish to participate in the proceeding, so that the filer need not serve the document on those participants separately. Therefore, applicants and other participants (or their counsel or representative) must apply for and receive a digital ID certificate before adjudicatory documents are filed so that they can obtain access to the documents via the E-Filing system. A person filing electronically using the NRC’s adjudicatory E-Filing system may seek assistance by contacting the NRC’s Electronic Filing Help Desk through the ‘‘Contact Us’’ link located on the NRC’s public website at https:// www.nrc.gov/site-help/esubmittals.html, by email to MSHD.Resource@nrc.gov, or by a tollfree call at 1–866–672–7640. The NRC Electronic Filing Help Desk is available between 9 a.m. and 6 p.m., Eastern Time, Monday through Friday, excluding government holidays. Participants who believe that they have a good cause for not submitting documents electronically must file an exemption request, in accordance with 10 CFR 2.302(g), with their initial paper filing stating why there is good cause for not filing electronically and requesting authorization to continue to submit documents in paper format. Such filings must be submitted by: (1) First class VerDate Sep<11>2014 16:56 Sep 09, 2019 Jkt 247001 mail addressed to the Office of the Secretary of the Commission, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001, Attention: Rulemaking and Adjudications Staff; or (2) courier, express mail, or expedited delivery service to the Office of the Secretary, 11555 Rockville Pike, Rockville, Maryland 20852, Attention: Rulemaking and Adjudications Staff. Participants filing adjudicatory documents in this manner are responsible for serving the document on all other participants. Filing is considered complete by first-class mail as of the time of deposit in the mail, or by courier, express mail, or expedited delivery service upon depositing the document with the provider of the service. A presiding officer, having granted an exemption request from using E-Filing, may require a participant or party to use E-Filing if the presiding officer subsequently determines that the reason for granting the exemption from use of E-Filing no longer exists. Documents submitted in adjudicatory proceedings will appear in the NRC’s electronic hearing docket which is available to the public at https:// adams.nrc.gov/ehd, unless excluded pursuant to an order of the Commission or the presiding officer. If you do not have an NRC-issued digital ID certificate as described above, click ‘‘cancel’’ when the link requests certificates and you will be automatically directed to the NRC’s electronic hearing dockets where you will be able to access any publicly available documents in a particular hearing docket. Participants are requested not to include personal privacy information, such as social security numbers, home addresses, or personal phone numbers in their filings, unless an NRC regulation or other law requires submission of such information. For example, in some instances, individuals provide home addresses in order to demonstrate proximity to a facility or site. With respect to copyrighted works, except for limited excerpts that serve the purpose of the adjudicatory filings and would constitute a Fair Use application, participants are requested not to include copyrighted materials in their submission. Energy Northwest, Docket No. 50–397, Columbia Generating Station, Benton County, Washington Date of amendment request: August 15, 2019, as supplemented by letters dated August 16, 2019; August 19, 2019; and August 20, 2019. Description of amendment: The amendment added a one-time extension to the Completion Time of Technical PO 00000 Frm 00084 Fmt 4703 Sfmt 4703 47557 Specification Action 3.8.7.A from 8 hours to 16 hours. Date of issuance: August 26, 2019. Effective date: As of the date of issuance and shall be implemented from the issuance date until 0800 Pacific Standard Time on September 14, 2019. Amendment No.: 254. A publiclyavailable version is in ADAMS under Accession No. ML19234A016; documents related to this amendment are listed in the Safety Evaluation enclosed with the amendment. Renewed Facility Operating License No. NPF–21: The amendment revised the Renewed Facility Operating License and Technical Specifications. Public comments requested as to proposed no significant hazards consideration (NSHC): Yes. Public notice of the proposed amendment was published in the Tri-City Herald located in Kennewick, Washington, from August 18, 2019, through August 20, 2019. The notice provided an opportunity to submit comments on the Commission’s proposed NSHC determination. No comments have been received. The Commission’s related evaluation of the amendment, finding of exigent circumstances, State consultation, and final NSHC determination are contained in a Safety Evaluation dated August 26, 2019. Attorney for licensee: William A. Horin, Esq., Winston & Strawn, 1700 K Street NW, Washington, DC 20006– 3817. NRC Branch Chief: Robert J. Pascarelli. Dated at Rockville, Maryland, this 3rd day of September 2019. For the Nuclear Regulatory Commission. Jamie M. Heisserer, Acting Deputy Director, Division of Operating Reactor Licensing, Office of Nuclear Reactor Regulation. [FR Doc. 2019–19331 Filed 9–9–19; 8:45 am] BILLING CODE 7590–01–P NUCLEAR REGULATORY COMMISSION [Docket No. 50–608; NRC–2019–0173] SHINE Medical Technologies LLC Nuclear Regulatory Commission. ACTION: Operating license application; receipt and availability. AGENCY: The U.S. Nuclear Regulatory Commission (NRC) staff acknowledges receipt of an application submitted by SHINE Medical Technologies, LLC (SHINE), dated July 17, 2019, filed SUMMARY: E:\FR\FM\10SEN1.SGM 10SEN1 khammond on DSKBBV9HB2PROD with NOTICES 47558 Federal Register / Vol. 84, No. 175 / Tuesday, September 10, 2019 / Notices pursuant to the Atomic Energy Act of 1954, as amended, and the NRC’s regulations, for an operating license for the SHINE Medical Isotope Production Facility. DATES: This action takes effect on September 10, 2019. ADDRESSES: Please refer to Docket ID NRC–2019–0173 when contacting the NRC about the availability of information for this action. You may obtain publicly-available information related to this action by any of the following methods: • Federal Rulemaking Website: Go to https://www.regulations.gov/ and search for Docket ID NRC–2019–0173. Address questions about NRC docket IDs in Regulations.gov to Jennifer Borges; telephone: 301–287–9127; email: Jennifer.Borges@nrc.gov. For technical questions, contact the individual listed in the FOR FURTHER INFORMATION CONTACT section of this document. • NRC’s Agencywide Documents Access and Management System (ADAMS): You may obtain publiclyavailable documents online in the ADAMS Public Documents collection at https://www.nrc.gov/reading-rm/ adams.html. To begin the search, select ‘‘Begin Web-based ADAMS Search.’’ For problems with ADAMS, please contact the NRC’s Public Document Room (PDR) reference staff at 1–800–397–4209, 301– 415–4737, or by email to pdr.resource@ nrc.gov. The ADAMS accession number for each document referenced (if it is available in ADAMS) is provided the first time that it is mentioned in this document. • NRC’s PDR: You may examine and purchase copies of public documents at the NRC’s PDR, Room O1–F21, One White Flint North, 11555 Rockville Pike, Rockville, Maryland 20852. FOR FURTHER INFORMATION CONTACT: Steven T. Lynch, Office of Nuclear Reactor Regulation, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001, telephone: 301–415– 1524; email: Steven.Lynch@nrc.gov. SUPPLEMENTARY INFORMATION: By letter dated July 17, 2019 (ADAMS Accession No. ML19211C044), SHINE filed with the NRC, pursuant to Section 103 of the Atomic Energy Act and part 50, ‘‘Domestic Licensing of Production and Utilization Facilities,’’ of title 10 of the Code of Federal Regulations (10 CFR), an application for an operating license for the SHINE Medical Isotope Production Facility to be located in Janesville, Wisconsin (ADAMS Package Accession No. ML19211C143). SHINE has proposed to construct and operate a facility in Janesville, Wisconsin for the production of VerDate Sep<11>2014 16:56 Sep 09, 2019 Jkt 247001 molybdenum-99 (Mo-99) through the irradiation and processing of a uranyl sulfate solution. As described in the operating license application, the proposed facility would comprise an irradiation facility and radioisotope production facility. The irradiation facility would consist of eight subcritical operating assemblies (or irradiation units), which would each be licensed as a utilization facility, as defined in 10 CFR 50.2, ‘‘Definitions,’’ and supporting structures, systems, and components (SSCs) for the irradiation of low enriched uranium. The radioisotope production facility would consist of hot cell structures, licensed collectively as a production facility, as defined in 10 CFR 50.2, and associated SSCs for the processing of irradiated material and extraction and purification of Mo-99. The irradiation facility and radioisotope production facility are collectively referred to as the SHINE Medical Isotope Production Facility. Issuance of the operating license would authorize the applicant to operate the SHINE Medical Isotope Production Facility for a 30-year period. By letters dated March 26 and May 31, 2013 (ADAMS Accession Nos. ML13088A192 and ML13172A361, respectively), SHINE (at the time known as SHINE Medical Technologies, Inc.) submitted a two-part construction permit application, as updated in 2015, for its eight utilization facilities and one production facility (ADAMS Package Accession No. ML15258A431). The NRC issued Construction Permit No. CPMIF– 001 to SHINE on February 29, 2016 (ADAMS Package Accession No. ML16041A473). The acceptability of the tendered application for docketing and other matters, including an opportunity to request a hearing, will be the subject of subsequent Federal Register notices. Dated at Rockville, Maryland, this 5th day of September, 2019. For the Nuclear Regulatory Commission. Steven T. Lynch, Project Manager, Research and Test Reactors Licensing Branch, Division of Licensing Projects, Office of Nuclear Reactor Regulation. [FR Doc. 2019–19534 Filed 9–9–19; 8:45 am] BILLING CODE 7590–01–P NUCLEAR REGULATORY COMMISSION [Docket No. IA–19–007; NRC–2019–0169] Order Prohibiting Involvement in NRCLicensed Activities Nuclear Regulatory Commission. AGENCY: PO 00000 Frm 00085 Fmt 4703 Sfmt 4703 ACTION: Order; issuance. The U.S. Nuclear Regulatory Commission (NRC) is issuing an order prohibiting involvement in NRClicensed activities to Mr. Justin Roberts. Mr. Justin Roberts was an Assembler employed by Enrichment Technology United States at the Louisiana Energy Services (LES)(d/b/a URENCO USA UUSA or licensee) uranium enrichment facility. Mr. Justin Roberts engaged in deliberate misconduct that caused LES to be in violation of NRC’s regulations. SUMMARY: The Order prohibiting involvement in NRC-licensed activities was issued on September 5, 2019. DATES: Please refer to Docket ID NRC–2019–0169 when contacting the NRC about the availability of information regarding this document. You may obtain publicly-available information related to this document using any of the following methods: • Federal Rulemaking Website: Go to https://www.regulations.gov and search for Docket ID NRC–2019–0169. Address questions about NRC docket IDs in Regulations.gov to Jennifer Borges; telephone: 301–287–9127; email: Jennifer.Borges@nrc.gov. For technical questions, contact the individual listed in the FOR FURTHER INFORMATION CONTACT section of this document. • NRC’s Agencywide Documents Access and Management System (ADAMS): You may obtain publicly available documents online in the ADAMS Public Document collection at https://www.nrc.gov/reading-rm/ adams.html. To begin the search, select ‘‘Begin Web-based ADAMS Search.’’ For problems with ADAMS, contact the NRC’s Public Document Room (PDR) reference staff at 1–800–397–4209, 301– 415–4737, or by email to pdr.resource@ nrc.gov. • NRC’s PDR: You may examine and purchase copies of public documents at the NRC’s PDR, Room O1–F21, One White Flint North, 11555 Rockville Pike, Rockville, Maryland 20852. ADDRESSES: FOR FURTHER INFORMATION CONTACT: Thomas Marenchin, Office of Enforcement, U.S. Nuclear Regulatory Commission, Washington, DC 20555– 001; telephone: 301–287–9518, email: Thomas.Marenchin@nrc.gov. SUPPLEMENTARY INFORMATION: The text of the Order is attached. Dated at Rockville, Maryland, this 5th day of September, 2019. E:\FR\FM\10SEN1.SGM 10SEN1

Agencies

[Federal Register Volume 84, Number 175 (Tuesday, September 10, 2019)]
[Notices]
[Pages 47557-47558]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-19534]


-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION

[Docket No. 50-608; NRC-2019-0173]


SHINE Medical Technologies LLC

AGENCY: Nuclear Regulatory Commission.

ACTION: Operating license application; receipt and availability.

-----------------------------------------------------------------------

SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) staff 
acknowledges receipt of an application submitted by SHINE Medical 
Technologies, LLC (SHINE), dated July 17, 2019, filed

[[Page 47558]]

pursuant to the Atomic Energy Act of 1954, as amended, and the NRC's 
regulations, for an operating license for the SHINE Medical Isotope 
Production Facility.

DATES: This action takes effect on September 10, 2019.

ADDRESSES: Please refer to Docket ID NRC-2019-0173 when contacting the 
NRC about the availability of information for this action. You may 
obtain publicly-available information related to this action by any of 
the following methods:
     Federal Rulemaking Website: Go to https://www.regulations.gov/ and search for Docket ID NRC-2019-0173. Address 
questions about NRC docket IDs in Regulations.gov to Jennifer Borges; 
telephone: 301-287-9127; email: [email protected]. For technical 
questions, contact the individual listed in the FOR FURTHER INFORMATION 
CONTACT section of this document.
     NRC's Agencywide Documents Access and Management System 
(ADAMS): You may obtain publicly-available documents online in the 
ADAMS Public Documents collection at https://www.nrc.gov/reading-rm/adams.html. To begin the search, select ``Begin Web-based ADAMS 
Search.'' For problems with ADAMS, please contact the NRC's Public 
Document Room (PDR) reference staff at 1-800-397-4209, 301-415-4737, or 
by email to [email protected]. The ADAMS accession number for each 
document referenced (if it is available in ADAMS) is provided the first 
time that it is mentioned in this document.
     NRC's PDR: You may examine and purchase copies of public 
documents at the NRC's PDR, Room O1-F21, One White Flint North, 11555 
Rockville Pike, Rockville, Maryland 20852.

FOR FURTHER INFORMATION CONTACT: Steven T. Lynch, Office of Nuclear 
Reactor Regulation, U.S. Nuclear Regulatory Commission, Washington, DC 
20555-0001, telephone: 301-415-1524; email: [email protected].

SUPPLEMENTARY INFORMATION: By letter dated July 17, 2019 (ADAMS 
Accession No. ML19211C044), SHINE filed with the NRC, pursuant to 
Section 103 of the Atomic Energy Act and part 50, ``Domestic Licensing 
of Production and Utilization Facilities,'' of title 10 of the Code of 
Federal Regulations (10 CFR), an application for an operating license 
for the SHINE Medical Isotope Production Facility to be located in 
Janesville, Wisconsin (ADAMS Package Accession No. ML19211C143).
    SHINE has proposed to construct and operate a facility in 
Janesville, Wisconsin for the production of molybdenum-99 (Mo-99) 
through the irradiation and processing of a uranyl sulfate solution. As 
described in the operating license application, the proposed facility 
would comprise an irradiation facility and radioisotope production 
facility. The irradiation facility would consist of eight subcritical 
operating assemblies (or irradiation units), which would each be 
licensed as a utilization facility, as defined in 10 CFR 50.2, 
``Definitions,'' and supporting structures, systems, and components 
(SSCs) for the irradiation of low enriched uranium. The radioisotope 
production facility would consist of hot cell structures, licensed 
collectively as a production facility, as defined in 10 CFR 50.2, and 
associated SSCs for the processing of irradiated material and 
extraction and purification of Mo-99. The irradiation facility and 
radioisotope production facility are collectively referred to as the 
SHINE Medical Isotope Production Facility. Issuance of the operating 
license would authorize the applicant to operate the SHINE Medical 
Isotope Production Facility for a 30-year period.
    By letters dated March 26 and May 31, 2013 (ADAMS Accession Nos. 
ML13088A192 and ML13172A361, respectively), SHINE (at the time known as 
SHINE Medical Technologies, Inc.) submitted a two-part construction 
permit application, as updated in 2015, for its eight utilization 
facilities and one production facility (ADAMS Package Accession No. 
ML15258A431). The NRC issued Construction Permit No. CPMIF-001 to SHINE 
on February 29, 2016 (ADAMS Package Accession No. ML16041A473).
    The acceptability of the tendered application for docketing and 
other matters, including an opportunity to request a hearing, will be 
the subject of subsequent Federal Register notices.

    Dated at Rockville, Maryland, this 5th day of September, 2019.

    For the Nuclear Regulatory Commission.
Steven T. Lynch,
Project Manager, Research and Test Reactors Licensing Branch, Division 
of Licensing Projects, Office of Nuclear Reactor Regulation.
[FR Doc. 2019-19534 Filed 9-9-19; 8:45 am]
BILLING CODE 7590-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.